复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R575.2;R248

基金项目:


Clinical Study on Compound Biejia Ruangan Tablets Combined with Entecavir for Hepatitis B Cirrhosis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化的效果。方法:将乙肝肝硬化患者 210 例根据随机数字表法分为 2 组,各 105 例。2 组患者均给予综合护理干预,对照组加用恩替卡韦治疗,观察组给予复方鳖甲软肝片联合恩替卡韦治疗。观察比较 2 组治疗前后肝功能 [天门冬氨酸氨基转移酶 (AST)、丙氨酸氨基转移酶 (ALT)、总胆红素 (TBil) 及凝血酶原时间活动度(PTA)]、肝纤维化指标[透明质酸酶(HA)、层黏连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PC-Ⅲ)]、乙型肝炎 e 抗原(HBeAg)阳性率、乙型肝炎 e 抗体(HBeAb)阳性率及乙肝病毒脱氧核糖核酸(HBV-DNA)水平变化。结果:治疗后,2 组 AST、ALT、Tbil 水平均较治疗前明显降低 (P<0.05),PTA 水平升高 (P<0.05);且观察组各项指标改善较对照组更显著 (P<0.05)。治疗后,2 组 HA、LN、Ⅳ-C、PC-Ⅲ及 HBV-DNA 水平均较治疗前明显降低 (P<0.05),且观察组各项指标均低于对照组(P<0.05)。治疗后,观察组 HBeAg 阳性率较对照组降低,HBeAb 阳性率较对照组升高,差异均有统计学意义(P<0.05)。结论:复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化,能够有效改善患者的肝功能和肝纤维化指标,调节机体HBeAg 和 HBeAb 阳性表达,并能显著下调 HBV-DNA 水平。

    Abstract:

    Abstract:Objective:To observe the effect of compound Biejia Ruangan tablets combined with entecavir for hepatitis B cirrhosis. Methods:A total of 210 cases of patients with hepatitis B cirrhosis were divided into two groups according to the random number table method,105 cases in each group. Both groups were intervened with comprehensive nursing;the control group was additionally treated with entecavir, and the observation group was additionally treated with compound Biejia Ruangan tablets combined with entecavir. Before and after treatment, the changes in the liver function indexes including aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin(TBil) and prothrombin activity (PTA),the liver fibrosis indexes including hyaluronic acid(HA),laminin(LN),type Ⅳ collagen(Ⅳ-C) and procollagen type Ⅲ (PC-Ⅲ),as well as the positive rates of hepatitis B e-antigen(HBeAg) and hepatitis B e-antibody(HBeAb),and the levels of hepatitis B virus deoxyribonucleic acid(HBV- DNA) in the two groups were observed and compared. Results: After treatment, the levels of AST, ALT and TBIL in the two groups were significantly decreased when compared with those before treatment(P<0.05), and the PTA levels were increased(P<0.05); the improvement of the above indexes in the observation group was more significant than that in the control group(P<0.05). After treatment, the levels of HA, LN, Ⅳ-C,PC-Ⅲ and HBV-DNA in the two groups were significantly decreased when compared with those before treatment(P< 0.05),and the above indexes in the observation group were lower than those in the control group(P<0.05). After treatment, the positive rate of HBeAg in the observation group was decreased when compared with that in the control group,and the positive rate of HBeAb was increased,differences being significant(P<0.05). Conclusion:Compound Biejia Ruangan tablets combined with entecavir for hepatitis B cirrhosis can effectively improve levels of liver function and liver fibrosis indexes,regulate the positive expressions of HBeAg and HBeAb in the body,and can significantly down- regulate the levels of HBV-DNA.

    参考文献
    相似文献
    引证文献
引用本文

聂萌,卢文杰,王晶.复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化临床研究[J].新中医,2021,53(1):187-190

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-01-11
  • 出版日期: